Trial | Target | Treatment vs. control arm | Phase | Setting | Key results (Treatment vs. control) |
---|---|---|---|---|---|
Strategies targeting cell surface receptors | |||||
IMMU-132–01 [153] | Trop-2 inhibitor (Sacitizumab govitecan-hziy) | Sacitizumab govitecan-hziy | I/II | Heavily pretreated metastatic TNBC | Objective response rate 33.3% Median PFS 5.5 months |
ASCENT [154] | Trop-2 inhibitor (Sacitizumab govitecan-hziy) | Sacitizumab govitecan-hziy vs. Chemotherapy | III | Heavily pretreated metastatic TNBC | Median PFS 5.6 vs. 1.7 months HR 0.41 (95%CI 0.32–0.52; P < 0.001) |
NCT01969643 | LIV-1 Inhibitor (ladiratuzumab vedotin) | Ladiratuzumab vedotin | I | Advanced breast cancer | Ongoing Interim results: objective response rate of 32% |
NCT03310957 | LIV-1 Inhibitor (ladiratuzumab vedotin)  + PD1 inhibitor (pembrolizumab) | Ladiratuzumab vedotin  +  pembrolizumab | I/II | Advanced TNBC | Ongoing Primary endpoint is objective response rate Secondary endpoints include PFS and OS |
DESTINY-Breast04 [162] | Trastuzumab-deruxtecan (T-Dxd) | Trastuzumab-deruxtecan vs Chemotherapy (physician’s choice | III | Pretreated Her2-low, unresectable and/or metastatic breast cancer | Median PFS 9.9 vs. 5.1 months HR 0.51 (95%CI 0.40–0.64; P < 0.001) |